Citations

Clear

421 citation(s) found for "Short, C".

Short- and Long-Term Biological Variability of Small Dense LDL, HDL3, and Triglyceride-Rich Lipoprotein Cholesterol
Fatica, Erica M. , Jenkins, Sarah M. , Scott, Renee, Block, Darci R , Meeusen, Jeffrey W. , Baumann, N, Saenger, Amy K., Scott, Renee’ J, Baumann, Nikola A, Donato, Leslie J.

Mayo Clinic

The Journal of Applied Laboratory Medicine | May 11, 2022 | Volume: 7 | Issue: 5 | Pages: 1047-1061

10.1093/jalm/jfac039 | PMID 35899495 Get It

Abstract Background Measurement of cholesterol within lipoprotein subfractions may aid in cardiovascular disease prediction. Simple, homogenous enzymatic assays for the direct measurement of lipoprotein subfractions have been developed to measure small dense low-density lipoprotein cholesterol (sdLDL-C), high-density lipoprotein-3 cholesterol (HDL3-C), and triglyceride-rich lipoprotein (TRL-C) cholesterol. The objective of this study was to determine biological variability for sdLDL-C, HDL3-C, and TRL-C in a healthy reference population to facilitate interpretation of these analytes. Methods Serum samples were collected from 24 healthy subjects (n = 14 female/10 male) daily for 3 days while non-fasting, and daily for 5 days, weekly for 4 weeks, and monthly for 6 months after overnight fasting. sdLDL-C, HDL3-C, and TRL-C cholesterol were measured by homogenous enzymatic assays. Sources of variability (between-subject, within-subject, and analytical) were calculated using random-effects regression models. Reference change value (RCV) and index of individuality (II) for each time period were determined from the variance components. Results Analytic variability (daily, weekly, and monthly CVA) was <3% for each analyte. Monthly within-subject variability (CVI) was 17.1% for sdLDL-C, 7.4% for HDL3-C, and 25.7% for TRL-C. Most of the monthly variation was attributed to between-subject variation for all 3 analytes. Overall RCVs for monthly measurements were 18.1 mg/dL for sdLDL-C, 6.1 mg/dL for HDL3-C, and 16.0 mg/dL for TRL-C. IIs were <0.6 for sdLDL-C and HDL3-C, and 0.81 for TRL-C. Conclusions sdLDL-C, HDL3-C, and TRL-C showed moderate within-subject variability, but high between-subject variability, in a healthy reference population. Given the high individuality of each analyte, population-based reference intervals may be inadequate to detect clinically significant changes.
Influence of surgical technique in donor hepatectomy on immediate and short‐term living donor outcomes – A systematic review of the literature, meta‐analysis, and expert panel recommendations
Cheah, Yee Lee , Kwon, Choon Hyuck David , Pomposelli, James J. , Rudow, Dianne LaPointe , Bröering, Dieter C. , Spiro, Michael , Roberts, John P. , Group, the ERAS4OLT.org Working, Rudow, Dianne LaPointe , Roberts, John P , Heimbach, Julie K. , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | May 11, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14703 | PMID 35538019 Get It

AbstractBackgroundThere are currently no guidelines pertaining to ERAS pathways in living donor hepatectomy.ObjectivesThe aim of this study was to identify whether surgical technique influences immediate and short‐term outcomes after living liver donation surgery.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review and meta‐analysis following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel (CRD42021260707). Endpoints were mortality, overall complications, serious complications, bile eaks, pulmonary complications, estimated blood loss and length of stay.ResultsOf the 2410 screened articles, 21 articles were included for final analysis; three observational, 13 retrospective cohort, four prospective cohort studies, and one randomized trial. Overall complications were higher with right versus left hepatectomy (26.8% vs. 20.8%; OR 1.4, P = .010). Donors after left hepatectomy had shorter length of stay (MD 1.4 days) compared to right hepatectomy. There was no difference in outcomes after right donor hepatectomy with versus without middle hepatic vein. We had limited data on the influence of incision type and minimally invasive approaches on living donor outcomes, and no data on the effect of operative time on donor outcomes.ConclusionsLeft donor hepatectomy should be preferred over right hepatectomy, as it is related to improved donor short‐term outcomes (QOE; Moderate | Grade of Recommendation; Strong). Right donor hepatectomy with or without MHV has equivalent outcomes (QOE; Moderate | Grade of Recommendation; Strong); no preference is recommended, decision should be based on program's experience and expertise. No difference in outcomes was observed related to incision type, minimally invasive vs. open (QOE; Low | Grade of Recommendation; Weak); no preference can be recommended.
Does endoscopic mean safer? A comparison of the short-term safety of endoscopic versus laparoscopic bariatric therapies
Fayad, Lea , Schweitzer, Michael , Itani, Mohamad I. , Farha, Jad , Hedjoudje, Abdellah , Badurdeen, Dilhana, Kumbhari, Vivek

Mayo Clinic

Endoscopy International Open | April 14, 2022 | Volume: 10 | Issue: 04 | Pages: E307-E310

10.1055/a-1783-8573 | PMID 35433204 Get It

Abstract Background and study aims There is minimal research on real-world, large-volume data comparing endoscopic bariatric therapy (EBT) to laparoscopic bariatric therapy (LBT). This study aimed to compare 30-day postoperative morbidity and mortality outcomes of primary EBT vs LBT using the Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program. Patients and methods Patients aged 18 to 80 with body mass index (BMI) 35 to 40 kg/m2 undergoing primary procedures were included. Propensity score matching 1:50 was performed for EBT versus LBT based on age, sex, and BMI. Results We matched 211 EBTs with 9,059 LBTs. Operative length (63.9, 95 % confidence interval [CI]: 57.9, 69.8 versus 81.1, 95 % CI: 80.1, 82.1) and length of stay (0.49 days, 95 % CI: 0.29, 0.69 versus 1.43 days, 95 % CI: 1.41, 1.45) were significantly lower in the EBT group than the LBT group. There was no difference between EBT and LBT in the odds of readmission (odds ratio [OR] = 0.31, 95 % CI: 0.08, 1.25), reoperation (OR = 0.39, 95 % CI: 0.05, 2.84), or reintervention (OR = 0.98, 95 % CI: 0.24, 3.99). After controlling for chronic obstructive pulmonary disease, sleep apnea, history of myocardial infarction, hypertension requiring medications, and diabetes, EBT continued to be associated with lower odds of having any adverse event (AE) than LBT, with an OR of 0.34 (95 % CI: 0.16, 0.69). Subgroup analysis comparing EBT to laparoscopic sleeve gastrectomy (LSG) showed that EBT was associated with a lower risk having any AE than LSG, with an OR of 0.39 (95 % CI: 0.19, 0.79). Conclusions EBT is associated with a lower 30-day AE rate and shorter procedural length and length of stay than LBT, with similar rates of readmission, reintervention, and reoperation.
Short Bowel Syndrome in Adults
Bering, Jamie , DiBaise, John K.

Mayo Clinic

American Journal of Gastroenterology | April 5, 2022 | Volume: 117 | Issue: 6 | Pages: 876-883

10.14309/ajg.0000000000001763 | PMID 35383576 Get It

Short bowel syndrome (SBS) is a rare disorder characterized by severe intestinal dysfunction leading to malabsorption of macronutrients and micronutrients that often results in permanent need of parenteral nutrition support. Patients can develop SBS because of massive intestinal resection or loss of intestinal function and consequently experience significant morbidity and increased healthcare utilization. The remaining anatomy and length of bowel after intestinal resection have important prognostic and therapeutic implications. Because patients with SBS constitute a heterogenous group, management is complex and multifaceted, involving nutrition support, fluid and electrolyte management, and pharmacologic therapies in particular to control diarrhea. Surgical interventions including intestinal transplantation may be considered in selected individuals. Successful care of these patients is best accomplished by a multidisciplinary team that is experienced in the management of this syndrome.
Letter: The Modern Evolution of Simulations in Endovascular Neurosurgery—A Short Review
Ghozy, Sherief , Ghozy, Sherief , Azzam, Ahmed Y , Dmytriw, Adam A.

Mayo Clinic

Neurosurgery | March 25, 2022 | Volume: 90 | Issue: 6 | Pages: e182-e183

10.1227/neu.0000000000001946 | PMID 35333211 Get It

Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia
Pettigrew, Melinda M. , Kwon, Jiye , Gent, Janneane F., Kong, Yong , Wade, Martina , Creech, C. Buddy , Pan, Qing , Walter, Emmanuel B. , Martin, Judith M. , Gerber, Jeffrey S. , Newland, Jason G. , Hofto, Meghan E. , Staat, Mary Allen , Fowler, Vance G. , Chambers, Henry F. , Pettigrew, M M , Martin, J M , Staat, Mary A , Williams, Derek J. , Evans, Scott , Fowler, Vance G. , Huskins, W. Charles

Mayo Clinic

mBio | March 24, 2022 | Volume: 13 | Issue: 2 | Pages: No page available

10.1128/mbio.00195-22 | PMID 35323040 Get It

Antibiotic resistance is a major threat to public health. Treatment strategies involving shorter antibiotic courses have been proposed as a strategy to lower the potential for antibiotic resistance.
The role of preoperative optimization of the nutritional status on the improvement of short‐term outcomes after liver transplantation? A review of the literature and expert panel recommendations
Victor, David W. , Towey, Jennifer , Spiro, Michael , Burra, Patrizia , Group, the ERAS4OLT.org Working, Zanetto, Alberto , Montaño‐Loza, Aldo J. , Heimbach, Julie K. , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | March 18, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14647 | PMID 35303370 Get It

AbstractBackgroundMalnutrition is a known risk factor for postoperative morbidity and mortality in patients awaiting liver transplantation (LT). Malnutrition is a potentially reversible risk factor, though there are no clear guidelines on the best mechanism for an improvement. It also remains unclear if preoperative nutritional interventions have benefits to post‐transplant outcomes for transplant recipients.ObjectivesPrimary objective: To identify if preoperative optimization of nutritional status is associated with improved short‐term outcomes after LT. Secondary Objectives: To determine if preoperative improvement of malnutrition improves short‐term outcomes after LT, as well as if weight loss in obese patients affects short‐term outcomes after LT.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. POSPERO Protocol ID: CRD42021237450Results3851 records were identified in searching the databases, 3843 records were excluded by not fulfilling eligibility criteria. Seven full‐text articles were included for the final analysis of which three were randomized controlled trials, one was prospective observational studies, and three were retrospective observational studies. No appreciable difference in mortality, post‐transplant complication rate was noted across the studies. Length of stay (LOS) was noted to be shorter in two observational studies of Vitamin D deficiency in liver transplant patients.ConclusionsWe have made a weak recommendation supporting pre‐transplant nutritional supplementation due to possible benefit in reducing LOS as well as the lack of harm (Quality of Evidence low | Grade of Recommendation; Weak). No effective conclusions were reached for the secondary objectives due to the conflicting evidence.
Does multimodal perioperative pain management enhance immediate and short‐term outcomes after living donor partial hepatectomy? A systematic review of the literature and expert panel recommendations
Hogan, Brian , Planinsic, Raymond M. , Hillingsø, Jens , Ghani, Shahi , Fan, Ka Siu , Spiro, Michael , Vohra, Vijay , Auzinger, Georg , Group, the ERAS4OLT.org Working, Pai, Sher‐Lu , Suh, Kyung-Suk , Raptis, Dimitri , Group, the ERAS4OLT.org Working, Tinguely, Pascale

Mayo Clinic

Clinical Transplantation | March 17, 2022 | Volume: 36 | Issue: 10 | Pages: No page available

10.1111/ctr.14649 | PMID 35297508 Get It

AbstractBackgroundThe optimal analgesic strategy for patients undergoing donor hepatectomy is not known and the potential short‐ and long‐term physical and psychological consequences of complications are significant.ObjectivesTo identify whether a multimodal approach to pain of the donor intraoperatively enhances immediate and short‐term outcomes after living liver donation, and to provide international expert panel recommendations.Data sourcesOvid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central.MethodsSystematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel. PROSPERO 2021 CRD42021260699.ResultsNine studies assessing multi‐modal analgesia strategies were included in a qualitative assessment. Interventions included local, regional, and neuro‐axial anesthetic techniques, pharmacological intervention (NSAIDs, COX‐2 inhibitors, ketamine, dexmedetomidine, and lidocaine), and acupuncture. Overall, there was a significant (40%) reduction in opioid requirement on day 1 and a significant reduction in pain scores in the intervention vs control groups. Significant reductions in either length of stay or post‐operative complications were demonstrated in four of nine studies.ConclusionsOpioid use for patients undergoing donor hepatectomy is likely to impact both their short‐ and long‐term outcomes. To reduce post‐operative pain scores, shorten length of hospital stay, and promote earlier post‐operative return of bowel function, we recommend that multi‐modal analgesia be offered to patients undergoing living donor hepatectomy. Further research is required to confirm which multi‐modal techniques are most associated with enhanced recovery in living liver donors.
Surgical Trigger Finger Release Is Associated With New-Onset Dupuytren Contracture in the Short-Term Postoperative Period: A Matched Analysis
Maasarani, Samantha , Wee, Corinne, Lee, Christina D., Khalid, Syed , Layon, Sarah A. , Noland, Shelley S.

Mayo Clinic

HAND | March 7, 2022 | Volume: 18 | Issue: 7 | Pages: 1080-1088

10.1177/15589447221077375 | PMID 35253506 Get It

Background: This article compares the rates and time-to-development of new-onset Dupuytren disease in patients with trigger finger treated by steroid injection, surgical release, or both. Methods: PearlDiver’s Mariner 30 database was queried to identify patients with trigger finger between January 2010 and June 2019. One-to-one exact matching based on baseline patient demographics allowed us to create 4 identical groups defined by the type of trigger finger intervention received. Results: The matched population analyzed in this study consisted of 85 944 patients who were equally represented in the steroid injection cohort (n = 21 486, 25.00%), surgical release cohort (n = 21 486, 25.00%), steroids prior to surgery cohort (n = 21 486, 25.00%), and no intervention (control) cohort (n = 21 486, 25.00%). A new Dupuytren diagnosis after trigger finger treatment occurred in 1 in 128 patients overall, 1 in 156 patients treated with steroid injection, and 1 in 126 patients treated with surgical release. Trigger fingers treated by steroid injection only had the lowest rates of Dupuytren disease overall (n = 137, 0.64%, P = .0424) and treatment with fasciectomy (n = 14, 0.07%, P < .0005). In all, 171 patients in the surgery cohort developed Dupuytren disease 1 year after undergoing surgical trigger finger release. Furthermore, this cohort had the highest rates of fasciectomy (n = 55, 0.26%, P < .0005) and the lowest rates of no intervention (n = 103, 0.48%, P = .0471). Trigger fingers managed by surgical release developed Dupuytren disease (mean, 56.11 days; SD, 80.93 days, log-rank P = .02) and underwent fasciectomy (mean, 49.74 days; SD, 62.27 days; log-rank P < .0005) more quickly than all other cohorts. Conclusions: Patients solely undergoing surgical release of their trigger finger had significantly higher odds and expedited rate of developing new-onset Dupuytren disease overall and undergoing subsequent treatment by fasciectomy compared with trigger fingers managed by other interventions.